21st Century Cures Act

Last updated
21st Century Cures Act
Great Seal of the United States (obverse).svg
Other short titlesHelping Families in Mental Health Crisis Reform Act of 2016
Increasing Choice, Access, and Quality in Health Care for Americans Act
Long titleAn Act to accelerate the discovery, development, and delivery of 21st century cures, and for other purposes.
Enacted bythe 114th United States Congress
Citations
Public law Pub. L. Tooltip Public Law (United States)  114–255 (text) (PDF)
Legislative history

The 21st Century Cures Act is a United States law enacted by the 114th United States Congress in December 2016 and then signed into law on December 13, 2016. It authorized $6.3 billion in funding, mostly for the National Institutes of Health. [1] The act was supported especially by large pharmaceutical manufacturers and was opposed especially by some consumer organizations. [2]

Contents

The approval of drugs and devices would be streamlined, according to supporters, and treatments would reach the market more quickly. The argument made by opponents was that it would allow the marketing of riskier or less effective treatments by allowing the approval of drugs and devices on the basis of flimsier evidence, bypassing randomized, controlled trials. [3]

The bill incorporated the Helping Families In Mental Health Crisis Act, first introduced by then-Congressman Tim Murphy, R-Pa., which increased the availability of psychiatric hospital beds and established a new assistant secretary for mental health and substance use disorders. [4] [5]

Content

Research and drug development

Division A, titled "21st Century Cures," contains provisions related to National Institutes of Health funding and administration, reducing opioid abuse, medical research, and drug development. [6]

Opioid epidemic

The Comprehensive Addiction and Recovery Act (CARA) was passed a few months earlier. This act authorized many harm-reduction strategies, including increased access to the overdose reversal drug naloxone [7] for the opioid crisis, but didn't provide any federal funding for implementation. [8] The 21st Century Cures Act designated $1 billion in grants for states over two years to fight the opioid epidemic. [8] [9] The money may be used to improve prescription drug monitoring programs, [9] to make treatment programs more accessible, to train healthcare professionals in best practices of addiction treatment, and to research the most effective approaches to prevent dependency. [8] [9]

FDA drug approval process

The 21st Century Cures Act modified the FDA Drug Approval process. It was intended to expedite the process by which new drugs and devices are approved by easing the requirements put on drug companies looking for FDA approval on new products or new indications on existing drugs. For instance, under certain conditions, the act allows companies to provide "data summaries" and "real world evidence" such as observational studies, insurance claims data, patient input, and anecdotal data rather than full clinical trial results. [8] [10] [11]

Targeted drugs for rare diseases

The 21st Century Cures Act facilitates the development and approval of genetically targeted and variant protein targeted drugs for treatment of rare diseases. [12]

In section 3024, the 21st Century Cures Act allows researchers to waive the requirement for "informed consent" in cases where clinical testing of drugs or devices "poses no more than minimal risk" and "includes appropriate safeguards to protect the rights, safety, and welfare of the human subject." [12]

One example is a high-tech bandage that monitors blood flow. Standard procedure requires researchers to obtain the patient's permission before testing any new device on them. However, in this example, researchers might want to test the bandage on unconscious patients. In such circumstances, researchers may waive an informed consent requirement since the patient is still getting the standard, medically accepted care of blood pressure and heart rate monitoring. Researchers would still need to obey standard research protocols including institutional review boards to approve their research design and ethics. [8]

Human research subject protections

The 21st Century Cures Act calls on the Secretary of Health and Human Services to harmonize differences between the HHS Human Subject Regulations and FDA Human Subject Regulations. In so doing, the Secretary may change rules applying to vulnerable populations in order "to reduce regulatory duplication and unnecessary delays" and "modernize such provisions in the context of multisite and cooperative research projects."

Section 3023 provides for joint or shared review of research, review by institutional review boards other than that of the sponsor of research, and use of other means "to avoid duplication of effort." [12]

Medical research

The act allocates $4.8 billion to the National Institutes of Health for precision medicine and biomedical research. [1] [8] [10] Of this, $1.5 billion is earmarked for research on brain disease. [1] Another $1.8 billion is dedicated to cancer research in what is called the "Beau Biden Cancer Moonshot" initiative, named in honor of Vice President Joe Biden's son, who died of brain cancer in 2015. [1] [8] [13] [14] In October 2016, the Cohort Program was renamed as the All of Us Research Program. [15] [16] [17] (This is unrelated to the privately funded Cancer Breakthroughs 2020, also known as "Cancer Moonshot 2020".)

When Joe Biden became president, his administration revived the cancer initiative. On the 60th anniversary of the John F. Kennedy moonshot speech, President Biden gave a speech at the JFK library, promoting the revival of the Beau Biden Cancer Moonshot, including the new Advanced Research Projects Agency for Health. [18]

Strategic Petroleum Reserve sales

The act requires sale of 25 million barrels of crude oil (10,000,000 in 2017, 9,000,000 in 2018, and 6,000,000 in 2019) from the Strategic Petroleum Reserve. [19] [20] Revenue from these sales will provide part of the NIH funding provided in the law. [21]

Electronic health records information blocking

The Act defined interoperability and prohibited [22] information blocking. [23] Information blocking is defined as a practice that interferes with or prevents access to electronic health information, that is, information about a patient's medical history or treatment. [12] [24]

Under section 4004, information blocking can expose entities to fines of up to $1 million per violation. [12]

Medical software

Medical software is regulated as a medical device by the FDA in the Federal Food, Drug, and Cosmetic Act. [25] Section 3060 of the 21st Century Cures Act was created as an amendment to section 520 of the FD&C Act, which addressed how medical devices are defined. [26] [27] It outlined software functions that would be exempt from FDA regulation, such as those used for administrative purposes, encouraging a healthy lifestyle, electronic health records, clinical laboratory test results and related information, and clinical decision tools. [6] [28]

Behavioral health

Division B, titled "Helping Families in Mental Health Crisis," addresses the prevention and treatment of mental illnesses and substance abuse, treatment coverage, communication permitted by HIPAA, and interactions with law enforcement and the criminal justice system. [29]

The law strengthens mental health parity regulation, [9] which require insurance companies to cover mental health treatments to the same extent and in the same way as medical treatments. It also includes grants to provide community mental health resources, suicide prevention and intervention programs, and de-escalation training for law enforcement. [8] It also provides five-year grants for a demonstration program in which psychiatry residents and other mental health clinicians will practice in underserved areas. [9] Provisions for reform of HIPAA, elevating the standing of families in commitment decisions, and reforms of procedures for challenging release decisions, were not included in the final bill.

Some of these provisions were originally proposed in earlier bills, including the Mental Health Reform Act of 2016 (S. 2680); the Mental Health and Safe Communities Act of 2015 (H.R. 3722, S. 2002); the Helping Families in Mental Health Crisis Act of 2016 (H.R. 2646); the Comprehensive Justice and Mental Health Act of 2015 (H.R. 1854, S. 993); the Mental Health Awareness and Improvement Act of 2015 (H.R. 5327, S. 1893); the Justice and Mental Health Collaboration Act of 2015 (H.R. 731); and the Behavioral Health Care Integration Act of 2016 (H.R. 4388). [30]

Healthcare access and quality improvement

Division C, titled "Increasing Choice, Access, and Quality in Health Care for Americans," concerns Medicare programs and federal tax laws related to health plans for small employers. [31]

The Small Business HRA (QSEHRA)

The 21st Century Cures Act also included provisions that created a QSEHRA (Qualified Small Employer Health Reimbursement Arrangement), a more efficient way for small businesses and non-profits to offer health insurance to their employees.

Legislative history

The 21st Century Cures Act was originally introduced as H.R. 6 by Fred Upton (R–MI) on May 19, 2015. It passed the House on July 10, 2015, but did not pass in the Senate. [32] [33]

More than 1,400 registered lobbyists worked on this bill, representing more than 400 different organizations, [11] mostly pharmaceutical companies. [10]

Of 455 organizations registered to lobby on the bill, the top five by number of reports and specific issues according to OpenSecrets were:

The bill passed the House first by a wide margin. [35] Only five senators voted against it: Elizabeth Warren of Massachusetts; Bernie Sanders of Vermont; Ron Wyden and Jeff Merkley, both of Oregon, all Democrats; and Mike Lee, a Republican of Utah. [36] Warren, Sanders, and Merkley, in particular, objected to the pharmaceutical industry's influence on the bill. [2] In early December 2016, the act had support from both houses of congress. [37] [38]

President Obama signed the act on December 13, 2016. [39] The reasons stated for his support included combatting opioid abuse, advancing cancer research, advancing the BRAIN Initiative, advancing the Precision Medicine Initiative, and addressing bipartisan health issues. [39]

Reception

Stakeholders who praised the passing of the act include drug companies; medical device manufacturers; the National Institutes of Health; people advocating for lowered barriers to collecting human subject research data; Representatives Fred Upton (R-MI), Diana DeGette (D-CO), Timothy F. Murphy (R-PA); Senator Lamar Alexander (R-TN); and Vice President Joe Biden. [10] Hospitals and universities, [11] as well as the American Cancer Society Action Network, Research!America, and FasterCures supported the bill for its commitment toward funding research. [10] The American Psychological Association supported the bill due to its mental health provisions. [40] The Advanced Medical Technology Association supported the bill for easing the process of introducing new medical technologies. [10] The American Society of Human Genetics (ASHG) commended the passage of the bill for strengthened genetic privacy for research participants. [41] [42] [43] Prison Fellowship supported the bill due to its inclusion of the Comprehensive Justice and Mental Health Act, a portion designed to encourage collaboration among criminal justice, juvenile justice, mental health treatment, and substance abuse systems. [44] [45]

Stakeholders who criticized the passing of the act include the FDA, advocates for strong protections in clinical research, consumer organizations, and advocates of regenerative medicine. [10] The expedited drug approval process has been one topic of concern and debate. [1] The Public Citizen's Health Research Group and the National Center for Health Research campaigned against the Cures Act in fear that it will endanger public health by weakening FDA standards. [10] Senator Elizabeth Warren said that the bill had been "hijacked" by the pharmaceutical industry. She said the legislation watered down safety requirements for new drugs and devices and then, as a trade-off, called for research funding — at levels that must be appropriated on an annual basis. [10] John LaMattina, former head of Pfizer research and development and current commentator on the pharmaceutical industry, said that full clinical trials are necessary to prove effectiveness, and suggests some drugs may now be approved based on early data and only later proved ineffective. [11] The Public Citizen's Health Research Group says the designation of "breakthrough" devices is too broad, and could lead to clearance of devices that aren't ready for the market. [10]

Lupkin points out that the NIH's funding will need to be appropriated each year through the normal budget process, and therefore may be reduced from what this bill promised. [11] The NIH funding was actually less than many advocates hoped for, [10] [11] and earlier versions of the bill had promised.[ citation needed ]

One of the goals of the bill was streamlining approval, but Jerry Avorn and Aaron Kesselheim pointed out that a third of medicines are approved from a single clinical trial averaging fewer than 700 patients; [46] ultimately, however, the law did not allow real-world evidence for approving drugs, but rather for label expansions. [47]

See also

Related Research Articles

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

<span class="mw-page-title-main">Federal Food, Drug, and Cosmetic Act</span> Acts of the United States Congress

The United States Federal Food, Drug, and Cosmetic Act is a set of laws passed by the United States Congress in 1938 giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety of food, drugs, medical devices, and cosmetics. The FDA's principal representative with members of congress during its drafting was Charles W. Crawford. A principal author of this law was Royal S. Copeland, a three-term U.S. senator from New York. In 1968, the Electronic Product Radiation Control provisions were added to the FD&C. Also in that year the FDA formed the Drug Efficacy Study Implementation (DESI) to incorporate into FD&C regulations the recommendations from a National Academy of Sciences investigation of effectiveness of previously marketed drugs. The act has been amended many times, most recently to add requirements about bioterrorism preparations.

<span class="mw-page-title-main">Medical research</span> Wide array of research

Medical research, also known as health research, refers to the process of using scientific methods with the aim to produce knowledge about human diseases, the prevention and treatment of illness, and the promotion of health.

A drug recall removes a prescription or over-the-counter drug from the market. Drug recalls in the United States are made by the FDA or the creators of the drug when certain criteria are met. When a drug recall is made, the drug is removed from the market and potential legal action can be taken depending on the severity of the drug recall.

<span class="mw-page-title-main">Diana Zuckerman</span> American health policy analyst

Diana M. Zuckerman is an American health policy analyst who focuses on the implications of policies for public health and patients' health. She specializes in national health policy, particularly in women's health and the safety and effectiveness of medical products. She is the President of the National Center for Health Research and the Cancer Prevention and Treatment Fund.

The "war on cancer" is the effort to find a cure for cancer by increased research to improve the understanding of cancer biology and the development of more effective cancer treatments, such as targeted drug therapies. The aim of such efforts is to eradicate cancer as a major cause of death. The signing of the National Cancer Act of 1971 by United States president Richard Nixon is generally viewed as the beginning of this effort, though it was not described as a "war" in the legislation itself.

<span class="mw-page-title-main">Children in clinical research</span>

In health care, a clinical trial is a comparison test of a medication or other medical treatment, versus a placebo, other medications or devices, or the standard medical treatment for a patient's condition.

An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a drug prior to approval. It does not constitute approval of the drug in the full statutory meaning of the term, but instead authorizes the FDA to facilitate availability of an unapproved product, or an unapproved use of an approved product, during a declared state of emergency from one of several agencies or of a "material threat" by the Secretary of Homeland Security.

<span class="mw-page-title-main">Food and Drug Administration Modernization Act of 1997</span> US law

The United States Food and Drug Administration Modernization Act of 1997 (FDAMA) amended the Federal Food, Drug, and Cosmetic Act. This act is related to the regulation of food, drugs, devices, and biological products by the FDA. These changes were made in order to recognize the changes in the way the FDA would be operating in the 21st century. The main focus of this is the acknowledgment in the advancement of technological, trade, and public health complexities.

<span class="mw-page-title-main">National Center for Health Research</span> Organization

The National Center for Health Research is a Washington, D.C.-based non-profit organization founded in 1999, providing health-related services such as providing free information and training based on research findings; educating policy makers and working with the media. The President of the organisation is Diana Zuckerman. The primary program is The Cancer Prevention and Treatment Fund, which utilises an online health hotline.

<span class="mw-page-title-main">Dan Riskin</span> American entrepreneur and surgeon (born 1971)

Dan Riskin is an American entrepreneur and surgeon. As an expert in healthcare artificial intelligence, Riskin has promoted healthcare quality improvement and helped shape policy in the US and globally. Riskin's companies, featured in Forbes and The Wall Street Journal, have influenced the care of millions of patients. He continues to practice, teach, and perform research as Clinical Professor of Surgery at Stanford University.

The Food and Drug Administration is a federal agency of the United States, formed in 1930.

The Antibiotic Development to Advance Patient Treatment (ADAPT) Act was introduced in the U.S. Congress on December 12, 2013 by Representative Phil Gingrey of Georgia and fifty-two cosponsors. Responding to the lack of financial incentives for drug manufacturers to innovate new antibiotics and antifungals and the regulatory barriers to their doing so, it proposed an expedited pathway for testing drugs intended for diseases for which no cure yet existed. After it died in committee, a similar version of the Act was re-introduced by Representative John Shimkus of Illinois and his cosponsor Representative Gene Green of Texas. Though this Act likewise failed to make it out of committee, several of its provisions were codified in the 21st Century Cures Act, which was signed into law on December 13, 2016. These include the expedited testing pathway for new antibiotics and a similar provision for antimicrobial susceptibility tests.

<span class="mw-page-title-main">Cancer Breakthroughs 2020</span>

Cancer Breakthroughs 2020, also known as Cancer Moonshot 2020 is a coalition with the goal of finding vaccine-based immunotherapies against cancer. By pooling the resources of multinational pharmaceutical, biotechnology companies, academic centers and oncologists, it intends to create access to over 60 novel and approved agents under exploration in the war against cancer and is expected to enable rapid testing of novel immunotherapy combination protocols. The initiative is being managed by a consortium of companies called The National Immunotherapy Coalition.

<span class="mw-page-title-main">Janet Woodcock</span> American physician

Janet Woodcock is an American physician serving as Principal Deputy Commissioner of Food and Drugs, having previously served as Acting Commissioner of the U.S. Food and Drug Administration (FDA). She joined the FDA in 1986, and has held a number of senior leadership positions there, including terms as the Director of Center for Drug Evaluation and Research (CDER) from 1994 to 2004 and 2007 to 2021.

The US carries out 46% of global research and development (R&D) in the life sciences, making it the world leader in medical research.

Real-world evidence (RWE) in medicine is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). RWE can be generated by different study designs or analyses, including but not limited to, randomized trials, including large simple trials, pragmatic trials, and retrospective or prospective observational studies. In the USA the 21st Century Cures Act required the FDA to expand the role of real world evidence.

<span class="mw-page-title-main">Over-the-Counter Hearing Aid Act of 2017</span>

The Over-the-Counter Hearing Aid Act of 2017 was a law passed by the 115th United States Congress as a rider on the FDA Reauthorization Act of 2017. It created a class of hearing aids regulated by the Food and Drug Administration (FDA) available directly to consumers without involvement from a licensed professional. Regulations for this new class of hearing aid are expected to be released by the end of 2020.

<span class="mw-page-title-main">Medical Marijuana and Cannabidiol Research Expansion Act</span>

The Medical Marijuana and Cannabidiol Research Expansion Act is an Act of Congress allowing medical research on cannabis. The act is "the first standalone marijuana-related bill approved by both chambers of the United States Congress".

References

  1. 1 2 3 4 5 "Learn from Cures Act bipartisanship". Editorial. Asbury Park Press. Asbury Park, NJ: Gannett. 17 December 2016. Retrieved 31 December 2016.
  2. 1 2 Mukherjee, Sy (7 December 2016). "Everything You Need to Know About the Massive Health Reform Law That Just Passed Congress". Fortune. Retrieved 14 December 2016.
  3. ↑ With media watchdogs on the sidelines, pharma-funded advocacy groups pushed Cures Act to the finish line. Trudy Lieberman, HealthNewsReview, December 6, 2016
  4. ↑ Congress Is on the Verge of Passing a Landmark Mental Health Bill
  5. ↑ "House Passes Most Significant Mental Health Reform Bill in Decades". NBC News . 17 July 2016. Archived from the original on 2022-12-25.
  6. 1 2 H.R. 34 Division A—21st Century Cures
  7. ↑ "The Comprehensive Addiction and Recovery Act (CARA)". Community Anti-Drug Coalitions of America. Retrieved 14 October 2020.
  8. 1 2 3 4 5 6 7 8 Jacoby, Sarah (December 16, 2016). "What The Controversial 21st Century Cures Act Means For You". Refinery29. Retrieved 31 December 2016.
  9. 1 2 3 4 5 Levin, Aaron (December 30, 2016). "Obama Signs Landmark Legislation With Major Mental Health Provisions". Psychiatric News. 52 (1): 1. doi:10.1176/appi.pn.2017.1a10.
  10. 1 2 3 4 5 6 7 8 9 10 11 Kaplan, Sheila (5 December 2016). "Winners and losers of the 21st Century Cures Act". STAT News. Retrieved 31 December 2016.
  11. 1 2 3 4 5 6 Franz, Julia (December 25, 2016). "America's new 21st Century Cures Act will speed up drug approvals. Is that a good thing?". PRI. Retrieved 2016-12-31.
  12. 1 2 3 4 5 "PUBLIC LAW 114–255—DEC. 13, 2016" (PDF). www.govinfo.gov. U.S. Government Publishing Office. Retrieved 2 October 2021.
  13. ↑ Biden, Joe; Obama, Barack (13 December 2016). "Remarks by the President and the Vice President at the 21st Century Cures Act Bill Signing" (Press release). Washington, DC: The White House, Office of the Press Secretary. Retrieved 31 December 2016.
  14. ↑ "AACR Commends President Obama for Signing the 21st Century Cures Act" (Press release). Philadelphia, PA: American Association for Cancer Research. 13 December 2016. Retrieved 2016-12-31.
  15. ↑ "All of Us (project web page)". U.S. Department of Health & Human Services - National Institutes of Health. 2018. Retrieved 20 January 2018.
  16. ↑ Muoio, Dave (7 November 2017). "Fitbit wearables will help power NIH's All of Us Research Program". MobiHealthNews. Retrieved 20 January 2018.
  17. ↑ "NIH Partners With 14 Community Groups, Healthcare Associations on Outreach for All of Us Program". GenomeWeb. 17 November 2017. Retrieved 20 January 2018.
  18. ↑ Jessica Bartlett (September 12, 2022). "Channeling JFK in Boston visit, Biden breathes new life into cancer 'moonshot'". The Boston Globe .
  19. ↑ "This Week in Petroleum". US Department of Energy. 21 December 2016. Retrieved 21 December 2016.
  20. ↑ H.R. 34, Sec. 5010. Strategic Petroleum Reserve Drawdown.
  21. ↑ Lupkin, Sydney (25 November 2016). "Legislation That Would Shape FDA And NIH Triggers Lobbying Frenzy". Shots: Health News from NPR. National Public Radio.
  22. ↑ 21st Century Cures Act, 42 USC § 300jj-52(a)(1)(A) (2016).
  23. ↑ Black, Jennifer R.; Hulkower, Rachel L.; Ramanathan, Tara (2018-08-22). "Health Information Blocking: Responses Under the 21st Century Cures Act". Public Health Reports. 133 (5): 610–613. doi:10.1177/0033354918791544. ISSN   0033-3549. PMC   6134556 . PMID   30134128.
  24. ↑ "What is an electronic health record (EHR)? | HealthIT.gov". www.healthit.gov. Retrieved 2 October 2021.
  25. ↑ Health, Center for Devices and Radiological (2020-09-09). "What are examples of Software as a Medical Device?". FDA.
  26. ↑ Guidance for Industry and Food and Drug Administration Staff. "Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act". Food and Drug Administration .
  27. ↑ Health, Center for Devices and Radiological (2019-09-30). "Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act". U.S. Food and Drug Administration. Retrieved 2020-12-05.
  28. ↑ Evans, Barbara; Ossorio, Pilar (2018-08-14). "The Challenge of Regulating Clinical Decision Support Software After 21st Century Cures". American Journal of Law & Medicine. 44 (2–3): 237–251. doi:10.1177/0098858818789418. PMID   30106648. S2CID   52006753.
  29. ↑ H.R. 34 Division B—Helping Families in Mental Health Crisis
  30. ↑ "H.R. 34 (114th): 21st Century Cures Act". GovTrack. Civic Impulse, LLC. Retrieved January 10, 2017.
  31. ↑ H.R. 34 Division C—Increasing Choice, Access, and Quality in Health Care for Americans
  32. ↑ "Actions - H.R.6 - 114th Congress (2015-2016): 21st Century Cures Act". Congress.gov. Library of Congress. July 13, 2015. Retrieved 2017-01-10.
  33. ↑ "21st Century Cures Act (Public Law 114-255)". SciPol.org. 2016-12-14. Retrieved 2020-12-05.
  34. ↑ "Lobbying Spending Database H.R.6 , 2014 | OpenSecrets".
  35. ↑ Kaplan, Sheila (30 November 2016). "House approves the 21st Century Cures Act, sending landmark bill to Senate". Stat.
  36. ↑ Roll call vote 157 , via Senate.gov
  37. ↑ Pear, Robert (8 December 2016). "Cures Act Gains Bipartisan Support That Eluded Obama Health Law". The New York Times. Retrieved 14 December 2016.
  38. ↑ Ornstein, Norm (2015-07-13). "Congress Achieves a Rare Bipartisan Victory for Science". The Atlantic. Retrieved 2016-12-14.
  39. 1 2 Somanader, Tanya (13 December 2016). "3 Letters That Explain Why President Obama Is Signing the Cures Act". whitehouse.gov . Retrieved 2016-12-14– via National Archives.
  40. ↑ Sliwa, Jim (1 December 2016). "APA Hails House Passage Of Mental Health Provisions In 21st Century Cures Act" (Press release). Washington, DC: American Psychological Association. Retrieved 31 December 2016.
  41. ↑ Padmanabhan, Nalini (7 December 2016). "ASHG Supports Genetic Privacy Provisions in 21st Century Cures Act" (Press release). Bethesda, MD: American Society of Human Genetics. Retrieved 2 January 2017.
  42. ↑ Thompson, Dennis (8 December 2016). "Congress passes 21st Century Cures Act with billions for new research, treatments". CBS News. CBS Interactive Inc. Retrieved 2 January 2017.
  43. ↑ Enzi, Mike (15 December 2016). "Congress acts to protect the most personal data – genetic information". Opinion. Pine Bluffs Post. Vol. 108, no. 50. Pine Bluffs, WY. Retrieved 2 January 2017.
  44. ↑ DeRoche, Craig (29 November 2016). "Urgent need for support for 21st Century Cures Act". PrisonTalk.com. Retrieved 22 February 2017.
  45. ↑ DeRoche, Craig (14 December 2016). "Dear Scotty". New Abolitionists Radio. Retrieved 22 February 2017.
  46. ↑ Avorn, Jerry; Kesselheim, Aaron S. (2015-06-25). "The 21st Century Cures Act — Will It Take Us Back in Time?". New England Journal of Medicine. 372 (26): 2473–2475. doi:10.1056/nejmp1506964. ISSN   0028-4793. PMID   26039522.
  47. ↑ "The Politics of the 21st Century Cures Act". In the Pipeline. 2016-12-09. Retrieved 2018-11-25.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.